- Home
- HNVR vs CRBU Comparison
HNVR vs CRBU Comparison
Compare HNVR & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNVR
- CRBU
- Stock Information
- Founded
- HNVR 2008
- CRBU 2011
- Country
- HNVR United States
- CRBU United States
- Employees
- HNVR N/A
- CRBU N/A
- Industry
- HNVR Commercial Banks
- CRBU Medicinal Chemicals and Botanical Products
- Sector
- HNVR Finance
- CRBU Health Care
- Exchange
- HNVR Nasdaq
- CRBU Nasdaq
- Market Cap
- HNVR 167.7M
- CRBU 165.8M
- IPO Year
- HNVR 2022
- CRBU 2021
- Fundamental
- Price
- HNVR $22.35
- CRBU $1.72
- Analyst Decision
- HNVR Buy
- CRBU Strong Buy
- Analyst Count
- HNVR 2
- CRBU 3
- Target Price
- HNVR $23.75
- CRBU $6.67
- AVG Volume (30 Days)
- HNVR 13.5K
- CRBU 656.9K
- Earning Date
- HNVR 10-22-2025
- CRBU 11-05-2025
- Dividend Yield
- HNVR 1.80%
- CRBU N/A
- EPS Growth
- HNVR N/A
- CRBU N/A
- EPS
- HNVR 1.53
- CRBU N/A
- Revenue
- HNVR $68,211,000.00
- CRBU $9,121,000.00
- Revenue This Year
- HNVR N/A
- CRBU $9.23
- Revenue Next Year
- HNVR $17.15
- CRBU N/A
- P/E Ratio
- HNVR $14.59
- CRBU N/A
- Revenue Growth
- HNVR 14.14
- CRBU N/A
- 52 Week Low
- HNVR $17.33
- CRBU $0.66
- 52 Week High
- HNVR $27.14
- CRBU $3.00
- Technical
- Relative Strength Index (RSI)
- HNVR 51.96
- CRBU 42.15
- Support Level
- HNVR $22.26
- CRBU $1.78
- Resistance Level
- HNVR $22.81
- CRBU $1.94
- Average True Range (ATR)
- HNVR 0.47
- CRBU 0.11
- MACD
- HNVR -0.03
- CRBU -0.02
- Stochastic Oscillator
- HNVR 21.30
- CRBU 1.33
About HNVR Hanover Bancorp Inc.
Hanover Bancorp Inc is a United States-based banking company. It offers a full range of financial services and employs a complete suite of consumer and commercial banking products and services, including multi-family and commercial mortgages, residential loans, business loans, and lines of credit.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.